More funding for cancer research in Seattle: Adaptive Biotechnologies raises $105M

Researchers from Seattle who are finding ways to eliminate cancer are bringing in some serious funding today. On the same day the Fred Hutchinson Cancer Research Center announced a $20 million donation from the family of CEO Jeff Bezos, Seattle-based Adaptive Biotechnologies announced a big $105 million investment. Adaptive, which had previously only raised $15 million, was… Read More

Thong Le

Biotech investor Thong Le named CEO of Accelerator Corp.

Thong Le has taken the helm of Accelerator Corp., the Seattle-based investment firm that bankrolls emerging startups in the biotechnology arena. Le has served on the board of the organization for the past six years, but with the shift to CEO he will take over day-to-day operations at a critical time. First priority, Accelerator —… Read More


Tumor paint startup Blaze Bioscience raises $9M to help surgeons pinpoint cancer cells

Blaze Bioscience has raised $9 million in fresh funding from individual investors, money that the Seattle spinoff of the Fred Hutchinson Cancer Research Center will use to continue development on an innovative product dubbed Tumor Paint. Total funding in the company, founded by Fred Hutch researcher Jim Olson, now stands at $19 million. The new… Read More


Money-losing Dendreon to cut 150 employees in bid to become ‘nimble’ biotech company

Once a rising star in Seattle’s biotechnology community, Dendreon Corp. announced Tuesday that it is reducing its staff by 15 percent in an effort to accelerate a path to profitability and operate “as a leaner, more nimble biotechnology company.” The cuts of about 150 people are the latest setback at Dendreon, which eliminated 500 jobs… Read More


Cancer research startup Immune Design pulls in $32.5 million, plans to raise more

Immune Design has reeled in $32.5 million in venture capital financing, with plans to raise up to $16.5 million more in the series C round if certain milestones are met. Investors in the round include The Column Group, Topspin Partners, as well as existing investors Alta Partners, Versant Ventures, Osage Partners and ProQuest Investment. “Immune Design… Read More


Tech Moves: Skype exec departs Microsoft; Frazier Healthcare taps new VC; etc.

—Skype executive Mark Gillett is leaving Microsoft, taking a new position at private equity firm Silver Lake, reports Kara Swisher at All Things D. Gillett previously worked at Silver Lake, and Swisher notes that he managed 2,500 developers. “Mark’s accomplishments at Skype have transformed the company,” said Silver Lake managing partner Egon Durban in a… Read More

Mitchell Gold

Ex-Dendreon CEO starts healthcare investment fund Alpine BioVentures

Former Dendreon CEO Mitch Gold has partnered with biotechnology stock researcher David Miller to create a new Seattle-based investment firm called Alpine BioVentures. The fund, which was started earlier this year, plans to invest in both public and private companies which are developing “significant innovations in healthcare technology which meaningfully improve the lives of patients.”… Read More


NanoString sets IPO range of $13-$15, plans to trade on Nasdaq under ticker NSTG

Seattle’s NanoString Technologies today set the terms for its upcoming initial public offering, with plans to sell shares in the range of $13 to $15 per share. The 138-person company, a maker of genomic analysis tools which spun out of genomics pioneer Leroy Hood’s Institute for Systems Biology in 2003, initially filed for an IPO last month…. Read More


Mobisante raises $4.2M for smartphone-based ultrasound imaging system

Mobisante, the Redmond-based company that makes ultrasound technology viewable on a smartphone or tablet, just pulled in $4.2 million in fresh funding to continue providing customers with a low-cost alternative to other expensive high-end portable ultrasound systems. Founded in 2009 by Sailesh Chutani — a former Microsoft mobile exec — and David Zar — a researcher at Washington… Read More


Medical device maker Ekos acquired in $180M deal

Ekos, a Bothell medical device maker whose catheter-based ultrasound devices are used to break up blood clots in legs, has been acquired by British pharmaceutical company BTG for $180 million. The deal also includes up to $40 million in additional payouts if milestones are met. In addition to Ekos, BTG also agreed to purchased Nordion’s… Read More

Bruce Montgomery

Bruce Montgomery biotech startup Cardeas Pharma raises $34 million

It has been a good week for the Seattle life sciences community. On Monday, Seattle genomics tool maker NanoString Technologies filed for an initial public offering that could raise up to $86 million. Now, comes word that Cardeas Pharma Corporation, a biopharmaceutical company led by Seattle biotech veteran Bruce Montgomery, has raised $34 million in funding…. Read More


Frazier buys pharmaceutical packaging company AndersonBrecon

Seattle venture capital firm Frazier Healthcare has joined with Philadelphia-based Packaging Coordinators to purchase AndersonBrecon, a leading contract pharmaceutical packing company. The unit had previously been owned by health services giant AmerisourceBergen Corporation. Packaging Coordinators is a portfolio company of Frazier, and the newly-combined entity will operate under the Packaging Coordinators name. “PCI has been on an aggressive… Read More


Theraclone raises $14M to ID rare human antibodies that could be used to fight disease

Seattle biotechnology company Theraclone Sciences has raised an additional $8 million in equity financing and $6 million in debt, bringing total investment in its series B funding to $50 million. Investors in the round included ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo. “Theraclone… Read More

Jim Olson

Blaze Bioscience raises $8.5M to help surgeons pinpoint cancer cells with ‘tumor paint’

Seattle biotechnology startup Blaze Bioscience has raised $8.5 million to continue developing technologies that  are designed to help surgeons more easily identify cancer cells in the body. Total funding in the company, with operations in the South Lake Union area of Seattle, now stands at $9.8 million. Blaze said that the money came from individual… Read More


Innovative Pulmonary changes name, raises $10M and moves to Minnesota

Innovative Pulmonary Solutions has a new name, a new round of cash and a new headquarters. The medical device company announced today that it has changed its name to Holaira and opened a new headquarters in Plymouth, Minnesota. It also raised $10 million from existing investors, including Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and… Read More

Michelle Burriss

OncoGenex finance chief resigns after ‘personal relationship’ develops with CEO

Michelle Burris, the chief financial officer at Bothell biotechnology company OncoGenex Pharmaceuticals, has resigned from her post after disclosing a “developing personal relationship” with CEO Scott Cormack. After the relationship was disclosed to the board, the company determined that Burris should hand over her executive duties to others in the company. She will continue to serve… Read More


NanoString lands $15.3M for genetic analysis system

NanoString Technologies continues to rake in new capital, announcing today that it has raised $15.3 million from Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group. Existing investors, including Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund and BioMed Ventures, also participated in the financing. The deal follows a $20 million financing round… Read More


Resolve Therapeutics lands $5.8M to crack the code on Lupus

Resolve Therapeutics, a 2-year-old Seattle biotechnology spin off from the University of Washington, has raised $5.8 million in new financing from  New Science Ventures, WRF Capital and Easton Capital. The company will use the funds to continue to develop therapeutics for the treatment of Lupus, a life-threatening autoimmune disease that affects 1.5 million people in the United… Read More


Cardiac Dimensions raises $5.8M, sets sights on Europe

Kirkland-based Cardiac Dimensions recently raised $5.8 million in equity, debt and warrants, in order to buy shares from a group of 17 investors, according to a SEC filing and an article on Xconomy. The company, which produces a medical device intended to treat congestive heart failure, got clearance to sell its first product in Europe last… Read More


Dendreon shares sink after plant closure, restructuring

Dendreon, the once-promising Seattle biotechnology company, is taking it on the chin today after announcing a restructuring that will cost more than 600 people their jobs; the closure of its manufacturing facility in Morris Plains, New Jersey and other cost-cutting measures. “This restructuring sets a new course forward for Dendreon, accelerating our path to profitability and… Read More


Nutritional products firm opens new Seattle headquarters

Econet, a South Korean investment holding company, has moved two of its nutritional products companies  into a new 70,000 square-foot headquarters in Seattle’s Belltown neighborhood at 3005 1st Avenue. The space was previously occupied by biotechnology company Dendreon. Univera and Unigen had been based in Lacey, Washington since 2004, and with the move to Seattle… Read More